Technical Data Sheet
The Appetite Crusher Stack
Also Known As: CagriSema, CagriSema combination, Cagrilintide semaglutide, AM833 NN9535, Amylin GLP-1 dual agonist, Dual obesity drug, CagriSema stack, Amylin analog + GLP-1 agonist, Anti-obesity dual therapy, CagriSema combo, Cagrilintide with semaglutide, cagrilintide + semaglutide
Scan To View Profile
| Evidence Tier | Investigational |
|---|---|
| Category | Weight Loss & Metabolism |
| Class | Fixed-ratio combination: long-acting amylin analog (cagrilintide) + GLP-1 receptor agonist (semaglutide) |
| Molecular Target | Amylin/calcitonin receptors (cagrilintide) + GLP-1 receptor (semaglutide); dual satiety and glucose regulation |
| Sequence | cagrilintide + semaglutide |
| Molecular Weight | combination |
| CAS | n/a |
| Parent | Cagrilintide and Semaglutide |
| Mechanism | It hits the brain from two different angles. It activates the GLP-1 switch (which controls blood sugar and cravings) and the Amylin switch (which controls physical fullness in the stomach). |
| Studied For | Obesity / overweight, Type 2 diabetes, Dual-mechanism weight loss, GLP-1 plus amylin dual therapy, Cardiometabolic disease, HbA1c reduction, Appetite suppression dual pathway, Body weight reduction, Metabolic syndrome, Insulin resistance, Blood sugar control, Caloric intake reduction research, Combination incretin amylin therapy, Cardiovascular risk reduction, obesity, appetite suppression, extreme weight loss, metabolic control |
| Administration Route | Injection Only |
| Form | lyophilized |
| Diluent | bacteriostatic or sterile water |
| Storage Temperature | frozen/refrigerated, dark |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | See component profiles. |
| Regulatory | Investigational (Novo Nordisk); NDA filed with FDA 18 Dec 2025 on the REDEFINE 1 and REDEFINE 2 pivotal trials and under FDA review through 2026; company guidance points to a decision in Q4 2026, and no PDUFA date has been publicly confirmed. Would be the first once-weekly GLP-1 plus amylin analogue combination for weight management if approved. Note that the Phase 3 REDEFINE 4 head-to-head trial did not meet its primary endpoint of non-inferiority on weight loss versus tirzepatide at 84 weeks. Not approved. |
| Sources |